Exelixis

This study tests whether a combination of two drugs, cabozantinib and atezolizumab, works better than the standard drug sorafenib for people with advanced liver cancer who haven't had other treatments. About 837 adults took part. The goal is to see if the combo slows cancer growt…

This study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as a higher dose (140 mg) in people with advanced medullary thyroid cancer that has spread. The goal is to see if the lower dose can control the cancer just as long while causing fewer side effec…

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. About 575 men who have already tried one hormone therapy will be …

This study tests whether a new drug combination (XL092 plus atezolizumab) works better than the current standard drug regorafenib for people with advanced colorectal cancer that has spread and is no longer responding to other treatments. About 900 adults with a specific type of c…

This study tests whether adding the targeted drug cabozantinib to a standard immunotherapy combo (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 adults with intermediate- or high-risk kidney cancer that has s…

This study tested whether the drug cabozantinib could help control advanced thyroid cancer that no longer responds to standard radioactive iodine treatment and has worsened after previous targeted therapies. Researchers compared cabozantinib against a placebo (inactive pill) in 1…